S. Mark Levine's most recent trade in Immunovant Inc was a trade of 3,650 Common Stock done at an average price of $25.5 . Disclosure was reported to the exchange on Nov. 20, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 20 Nov 2024 | 3,650 | 319,228 (0%) | 0% | 25.5 | 92,893 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 29.53 per share. | 23 Oct 2024 | 4,361 | 322,878 (0%) | 0% | 29.5 | 128,780 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.79 per share. | 16 Oct 2024 | 2,860 | 327,239 (0%) | 0% | 28.8 | 82,339 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 21 Aug 2024 | 3,164 | 330,230 (0%) | 0% | 31.8 | 100,742 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 32.32 per share. | 21 Aug 2024 | 131 | 330,099 (0%) | 0% | 32.3 | 4,234 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 24 Jul 2024 | 4,015 | 333,394 (0%) | 0% | 27.8 | 111,456 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 29.64 per share. | 17 Jul 2024 | 2,358 | 337,556 (0%) | 0% | 29.6 | 69,891 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 30.55 per share. | 17 Jul 2024 | 147 | 337,409 (0%) | 0% | 30.6 | 4,491 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 29.65 per share. | 22 May 2024 | 3,242 | 339,914 (0%) | 0% | 29.6 | 96,125 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.90 per share. | 24 Apr 2024 | 3,963 | 343,156 (0%) | 0% | 28.9 | 114,531 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.80 per share. | 17 Apr 2024 | 7,602 | 349,344 (0%) | 0% | 28.8 | 218,938 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 29.94 per share. | 17 Apr 2024 | 2,225 | 347,119 (0%) | 0% | 29.9 | 66,617 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 68,723 | 68,723 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 54,978 | 356,946 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | S. Levine Mark | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 36.15 per share. | 22 Feb 2024 | 2,134 | 301,968 (0%) | 0% | 36.1 | 77,144 | Common Stock |
| Immunovant Inc | S. Levine Mark | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 37.91 per share. | 26 Jan 2024 | 2,981 | 304,148 (0%) | 0% | 37.9 | 113,010 | Common Stock |
| Immunovant Inc | S. Mark Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 38.46 per share. | 26 Jan 2024 | 46 | 304,102 (0%) | 0% | 38.5 | 1,769 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 20.30 per share. | 24 Aug 2023 | 12,285 | 314,489 (0%) | 0% | 20.3 | 249,386 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 24 Aug 2023 | 1 | 314,488 (0%) | 0% | 21 | 21 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.63 per share. | 26 Jul 2023 | 3,917 | 326,774 (0%) | 0% | 21.6 | 84,725 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 16.29 per share. | 25 Apr 2023 | 2,633 | 330,691 (0%) | 0% | 16.3 | 42,892 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 113,821 | 113,821 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 87,664 | 333,324 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.51 per share. | 26 Jan 2023 | 10,156 | 245,660 (0%) | 0% | 18.5 | 187,988 | Common Stock |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 169,648 | 169,648 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 112,816 | 255,816 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 383,000 | 383,000 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Mark S. Levine | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 143,000 | 143,000 (0%) | 0% | 0 | Common Stock |